NASDAQ: RKDAArcadia Biosciences Inc Stock
$4.74-0.07 (-1.46%)
Updated Feb 14, 2025
RKDA Price
$4.74
Fair Value Price
N/A
Market Cap
$6.47M
52 Week Low
$1.85
52 Week High
$10.31
P/E
-1.14x
P/B
0.63x
P/S
0.71x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.27M
Earnings
-$5.83M
Gross Margin
40.1%
Operating Margin
-110.48%
Profit Margin
-110.6%
Debt to Equity
0.5
Operating Cash Flow
-$12M
Beta
0.92
Next Earnings
Mar 26, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RKDA Overview
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. It engages in developing crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The company was incorporated in 2002 and is headquartered in Davis, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RKDA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Value
B
Growth
C
Momentum
C
Sentiment
D
Safety
D
Financials
F
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Food
Industry Rating
B
RKDA
Ranked#47 of 61
Ranked#47 of 61
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $18.56 | A | |
| $5.64 | A | |
| $14.51 | A |
Be the first to know about important RKDA news, forecast changes, insider trades & much more!
RKDA News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RKDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RKDA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RKDA is good value based on its book value relative to its share price (0.63x), compared to the US Packaged Foods industry average (1.91x)
P/B vs Industry Valuation
RKDA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RKDA due diligence checks available for Premium users.
Valuation
RKDA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.14x
Industry
20.49x
Market
37.92x
RKDA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.63x
Industry
1.91x
RKDA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RKDA's financial health
Profit margin
Revenue
$1.5M
Net Income
-$1.6M
Profit Margin
-104.9%
RKDA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
RKDA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$15.2M
Liabilities
$5.1M
Debt to equity
0.5
RKDA's short-term assets ($10.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RKDA's short-term assets ($10.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RKDA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RKDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
$180.0k
Financing
$4.0k
RKDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RKDA vs Food Stocks
Arcadia Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.